BullFrog AI Announces Appointment of Chief Financial Officer
BullFrog AI Holdings (NASDAQ: BFRG) has appointed Josh Blacher as its new Chief Financial Officer, following the passing of former CFO Dane Saglio. Blacher brings over two decades of experience in strategic finance and corporate development for life science and biotech companies. His background includes roles as CFO at Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics, and senior positions at Teva Pharmaceuticals.
Blacher, who holds a BA in Economics from Yeshiva University and an MBA from Columbia Business School, will focus on strengthening the company's balance sheet, financial operations, and supporting strategic initiatives. His expertise includes SEC reporting, investor relations, and experience with both private and public companies.
BullFrog AI Holdings (NASDAQ: BFRG) ha nominato Josh Blacher come nuovo Chief Financial Officer, dopo la scomparsa dell'ex CFO Dane Saglio. Blacher porta con sé oltre vent'anni di esperienza nella finanza strategica e nello sviluppo aziendale per aziende nel settore delle scienze della vita e biotecnologie. Il suo background comprende ruoli come CFO presso Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics e posizioni di alto livello in Teva Pharmaceuticals.
Blacher, che possiede una laurea in Economia presso la Yeshiva University e un MBA presso la Columbia Business School, si concentrerà sul rafforzamento del bilancio dell'azienda, delle operazioni finanziarie e sul supporto delle iniziative strategiche. La sua esperienza include la reportistica SEC, le relazioni con gli investitori e una solida esperienza sia in aziende private che pubbliche.
BullFrog AI Holdings (NASDAQ: BFRG) ha nombrado a Josh Blacher como su nuevo Director Financiero, tras el fallecimiento del anterior CFO Dane Saglio. Blacher aporta más de dos décadas de experiencia en finanzas estratégicas y desarrollo corporativo para empresas de ciencias de la vida y biotecnología. Su trayectoria incluye roles como CFO en Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics y posiciones senior en Teva Pharmaceuticals.
Blacher, quien tiene una licenciatura en Economía de la Universidad Yeshiva y un MBA de la Escuela de Negocios de Columbia, se centrará en fortalecer el balance de la empresa, las operaciones financieras y el apoyo a iniciativas estratégicas. Su experiencia incluye informes a la SEC, relaciones con inversores y experiencia tanto en empresas privadas como públicas.
BullFrog AI Holdings (NASDAQ: BFRG)는 Josh Blacher를 새로운 최고 재무 책임자로 임명했습니다. 이는 이전 CFO인 Dane Saglio의 별세에 따른 결정입니다. Blacher는 생명 과학 및 생명공학 기업을 위한 전략적 재무 및 기업 개발 분야에서 20년 이상의 경험을 보유하고 있습니다. 그의 경력에는 Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics의 CFO 역할과 Teva Pharmaceuticals의 고위직이 포함됩니다.
Blacher는 Yeshiva University에서 경제학 학사, Columbia Business School에서 MBA를 보유하고 있으며, 회사의 재무 상태, 재무 운영 강화 및 전략적 이니셔티브 지원에 집중할 것입니다. 그의 전문성에는 SEC 보고, 투자자 관계 및 민간 및 공기업 모두에 대한 경험이 포함됩니다.
BullFrog AI Holdings (NASDAQ: BFRG) a nommé Josh Blacher comme nouveau directeur financier, suite au décès de l'ancien CFO Dane Saglio. Blacher possède plus de vingt ans d'expérience en finance stratégique et en développement de entreprises dans le secteur des sciences de la vie et de la biotechnologie. Son parcours comprend des postes de CFO chez Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics et des postes de haut niveau chez Teva Pharmaceuticals.
Blacher, qui détient un BA en économie de l'Université Yeshiva et un MBA de la Columbia Business School, se concentrera sur le renforcement du bilan de l'entreprise, des opérations financières et le soutien des initiatives stratégiques. Son expertise inclut la reporting auprès de la SEC, les relations investisseurs et une expérience tant dans des entreprises privées que publiques.
BullFrog AI Holdings (NASDAQ: BFRG) hat Josh Blacher zum neuen Chief Financial Officer ernannt, nach dem Tod des ehemaligen CFO Dane Saglio. Blacher bringt über zwei Jahrzehnte Erfahrung in strategischer Finanzierung und Unternehmensentwicklung für Unternehmen im Bereich der Lebenswissenschaften und Biotechnologie mit. Seine Vergangenheit umfasst Positionen als CFO bei Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics und leitende Positionen bei Teva Pharmaceuticals.
Blacher, der einen BA in Wirtschaftswissenschaften von der Yeshiva University und einen MBA von der Columbia Business School hat, wird sich darauf konzentrieren, die Bilanz des Unternehmens, die finanziellen Abläufe zu stärken und strategische Initiativen zu unterstützen. Seine Expertise umfasst SEC-Berichterstattung, Investorenbeziehungen und Erfahrung sowohl mit privaten als auch öffentlichen Unternehmen.
- Appointment of experienced CFO with over 20 years in life science and biotech financial management
- New CFO brings proven track record in capital raising and deal making
- Strong background in SEC reporting and investor relations for public companies
- None.
GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI’s former CFO, who recently lost his battle with cancer.
“Dane’s contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and a cherished friend. His wisdom, humility, and steadfast commitment to our mission will be deeply missed,” said Vin Singh, CEO of BullFrog AI. “At the same time, we are grateful to welcome Josh to our team at this pivotal moment. Josh’s extensive experience and leadership in financial strategy and corporate governance will be invaluable as we carry forward Dane’s legacy and advance our mission to revolutionize drug development.”
Mr. Blacher, with more than two decades of experience in strategic finance and corporate development for life science and biotech companies, brings to BullFrog AI a proven track record in financial stewardship, capital raising, operations and profitability, and deal making. He has successfully overseen SEC reporting and investor relations for both private and publicly traded companies. Most recently, he has served as CFO for Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics, and has previously held senior roles at Teva Pharmaceuticals, among others. Mr. Blacher earned his BA in Economics from Yeshiva University and an MBA in Finance from Columbia Business School.
In assuming the role of CFO, Mr. Blacher will build on the foundation laid by Mr. Saglio, focusing on enhancing the Company’s balance sheet strength, financial operations and supporting its strategic initiatives.
About BullFrog AI
BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at: https://bullfrogai.com.
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ
Who is the new CFO of BullFrog AI (BFRG) and when was he appointed?
What is Josh Blacher's professional background before joining BullFrog AI (BFRG)?
What are Josh Blacher's main responsibilities as BFRG's new CFO?
What educational qualifications does BFRG's new CFO Josh Blacher hold?
